A clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction?

Similar documents
Critically Appraised Topic. A clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction?

EDUCATIONAL COMMENTARY UPDATE ON ANAEROBES

Instant Anaerobe TM for Sherlock

PERANAN MIKROBIOLOGI DALAM DIAGNOSIS PENYAKIT INFEKSI. dr. Agus Eka Darwinata, Ph.D.

CLINICAL MICROBIOLOGY HOSPITAL LABORATORY PRACTICE

Evaluation of the Oxyrase OxyPlate Anaerobe Incubation System

Verification of Disk Diffusion Tests

Verification of Gradient Diffusion Strips

ANAEROBIC DENTAL INFECTIONS AND ADVANCE LABORATORY DIAGNOSIS: A MINI REVIEW

Antibiotic Susceptibility Testing (ABST/AST)

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

Can We Afford To Do Anaerobic Cultures and Identification? A Positive Point of View

Evaluation of the E Test for Susceptibility Testing

NordicAST Bacteroides AST Study 2018

ABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18

QUALITY CONTROL IN. Quality: Quality means meeting the pre-determined requirements of users for a particular substance or service.

Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing

6/21/2012 Speaker Hannah Wexler, PhD, Objectives Continuing Education Credit program and evaluation by 07/21/ an Archived Program 612an

Rapid Identification of Bacteroides fragilis with Bile and

Rapid Identification of Bacteroides fragilis with Bile and

CHAPTER 24. Immunology

Rapid Identification and Antimicrobial Susceptibility Profiling of Anaerobic Bacteria in Clinical Specimens

The Dream of Automating the Microbiology Lab

GenMark Diagnostics. eplex BLOOD CULTURE IDENTIFICATION (BCID): DESIGNED TO IMPROVE PATIENT CARE AND CLINICAL OUTCOMES

Dr. Hala Al Daghistani. (1) They are often contiguous with a mucosal surface.

Clinical and Microbiological Features of Necrotizing Fasciitis

Comparing Traditional Culture Methods and New Molecular Testing Techniques to Analyze Biofilm Composition on Uninfected IPPs

BD Schaedler Agar/Schaedler KV Agar with 5% Sheep Blood (Biplate)

Microbiology Section Pathology Resident Self Assessment Checklist. 2. Proper collection and specimen handling procedure.

Isolation of bacteria from diabetic foot ulcers with special reference to anaerobe isolation by simple two-step combustion technique in candle jar

WP8 Branka Bedenic, University Hospital Zagreb, Croatia Valentino D Onofrio, Jessa hospital and Hasselt University, Belgium

BD BBL TM CDC Anaerobe 5% Sheep Blood Agar

Evaluation of the BBL Crystal Anaerobe Identification System

Clinically Relevant Anaerobes

Blood cultures. Sept 2013 A/Prof John Ferguson (nepal)

Standard Operating Procedure

Dr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM

Bacterial load was measured using the method described previously (1). The necrotic tissue

BSAC Susceptibility Testing Residential Workshop

!Bio-Bag Environmental Chamber Type A

Anaerobic infections in surgical wards A two year study

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Overview. A day in the life. 8/31/2012. Walkthrough of a typical run. Training, maintenance and QC. Ah ha! moments

California Association for Medical Laboratory Technology. Distance Learning Program. ANAEROBIC BACTERIOLOGY FOR THE CLINICAL LABORATORY by

Project 7: Wound Cultures and Identification

JOHN DEMPSEY HOSPITAL Farmington, Connecticut ANTIBIOTIC SUSCEPTIBILITY PROFILES for INPATIENT Bacterial Isolates

Automated methods in the Microbiology Lab-Issues and Troubleshooting! Presented By: Dr B. Oboudi

Evaluation of the Carba NP Test for the Detection of Carbapenemase Activity in Bacteroides Species

Diagnostic Microbiology. dr. Agus Eka Darwinata, S.Ked., Ph.D

Example # 2. IQCP for Antimicrobial Susceptibility Testing (AST) Test System: Beckman Coulter Microscan Walkaway 96. Facility: Written by: Date:

IMPLEMENTATION OF EUCAST BREAKPOINTS

Two cases of Ruminococcus gnavus bacteremia associated with diverticulitis

Microbiology, Biofilms and Factors affecting Wound Healing. Professor Val Edwards-Jones Director of Research Manchester Metropolitan University

DEPARTMENT: MICROBIOLOGY PROGRAMME: B SC. Statements of Programme Specific Outcomes (PSOs)

Abstract... i. Committee Membership... iii. Foreword... vii. 1 Scope Introduction Standard Precautions References...

Blood cultures: past, present and future. Dr Natalia Solomon MD, FRCPSC Medical Microbiologist DynaLIFE Dx

Polymicrobial Infection in Mice

Selenium nanoparticles and their utilization in scaffolds. Prof. RNDr. Vojtech Adam, Ph.D. Mgr. Dagmar Hegerova, Ph.D. Mendel University in Brno

HKSH Introduces Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Biotyper

University of Groningen. Gram-positive anaerobic cocci Veloo, Alida

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

IQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST)

Multiple selective media for the isolation of anaerobic bacteria from clinical specimens

CLOSTRIDIA IN LABORATORY MEDICINE Deepali P. Danave 1, S. N. Kothadia 2, N. K. Shaikh 3

Recommended reading: Murray PR, editor: Medical Microbiology, ed 4, St Louis, 2002, Mosby, pages

HIMSS Davies Enterprise Application

Rapid Diagnostic Tests for Antimicrobial Resistance: Comparability of Results and Interpretation of Data

Combatting AMR: diagnostics

LABORATORY SKILLS. Unit 18 Microbiology Suite. Cambridge TECHNICALS LEVEL 3. D/507/6165 Guided learning hours: 60. ocr.org.

Automated methods in the Microbiology Lab-Issues and Troubleshooting!

Microbiology sheet (6)

National Center for Emerging and Zoonotic Infectious Diseases The Role of Breakpoint Committees for New Drugs Perspectives from the United States

Cystic Fibrosis and anaerobes. Dr Michael Tunney, Clinical & Practice Research Group, School of Pharmacy, Queen s University Belfast.

Susceptibility Tests

Report on New Patented Drugs - Invanz

Welsh Healthcare Associated Infection Programme (WHAIP)

Approximately 20% of the responding CLSI membership whose hospitals had greater than 200 beds was performing antifungal testing.

2015 EDITION. Selection. Publications. FAN Plus Media

SAMPLING AND DISPATCH OF SAMPLES

Laboratory Procedures in Clinical Microbiology

IDSA is pleased to offer the following comments on specific priority areas identified by FDA:

Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical

THE INHERENT CHALLENGES OF TESTING C. DIFFICILE

MLT 116L Clinical Microbiology Lab

Draft Guidance for Industry and FDA Staff Premarket Notification [510(k)] Submissions for Medical Devices that Include Antimicrobial Agents

Daily minimum Daily minimum. FiO What if the settings were as follows?

Abstract C th ICAAC, Chicago, September 2007

VITEK 2. Microbiology with Confidence

Biofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement

Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing Barenfanger J, Drake C, Kacich G

Project 5: Urine Cultures and Identification

MICROBIOLOGY SPECIMEN TRANSPORT GUIDELINES

Why is the workflow in Clinical Microbiology so slow? Can we get it quicker? Emmanuelle Cambau Hôpital Saint Louis, Paris 7, France

Outline. Introduction. Broth and Agar testing methods Automated susceptibility testing. Aims of antimicrobial susceptibility testing:

GENUS STAPHYLOCOCCUS: Isolation and Identification

Study Title Antimicrobial Activity and Efficacy of Seal Shield's Electroclave. Test Method Custom Device Study. Study Identification Number NG7233

Critical analysis of available data on use of antibiotics in aquaculture

Relevance of Routine Use of the Anaerobic Blood Culture Bottle

Abstract. Introduction. Materials and Methods

ADDITIONAL SPECIMEN TRANSPORT GUIDELINES

Transcription:

A clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction? Author: apr. Bart Peeters Supervisor: dr. Reinoud Cartuyvels Date: 19/05/2015

Content of this presentation Introduction Questions and methods a. Survey on anaerobic identification, reporting and AST procedures b. Multi-center retrospective case study of anaerobic cultures General conclusions To do/actions

Introduction Pathogenic role well established but often neglected Varying interest in anaerobic microbiology: 1960s: 1970s: 1980s: 2010s: Introduction of MALDI-TOF: Revolution -> Increasing amount of reported species and unfamiliar organisms -> Ignoring clinically significant results? -> Over-treating insignificant results?

Content of this presentation Introduction Questions and methods a. Survey on anaerobic identification, reporting and AST procedures b. Multi-center retrospective case study of anaerobic cultures General conclusions To do/actions

Questions and methods How do Belgian laboratories organize anaerobic ID, reporting and AST procedures? Web-based survey Are clinical decisions influenced by anaerobic culture results? Multi-center retrospective case study

Content of this presentation Introduction Questions and methods a. Survey on anaerobic identification, reporting and AST procedures b. Multi-center retrospective case study of anaerobic cultures General conclusions To do/actions

a. Survey on anaerobic identification, reporting and AST procedures 53 questioned laboratories (response degree 64%): Q1: From which samples do you perform anaerobic cultures? Q2: Do you use other rejection criteria besides sample type for performing anaerobic culture? Q3: In which documents do you mention rejection criteria for anaerobic culture? Q4: Do you use specific anaerobic collection or transport media? Q5: When do you perform a full identification (species level) of cultured anaerobic colony types? Q6: What is reported to the clinician if limited workup of an anaerobic culture is applied? Q7: Which identification methods are available for anaerobic bacteria in your laboratory? Q8: Which identification method is used for the vast majority of anaerobic bacteria? Q9: When do you report a full identification (species level) of strictly anaerobic bacteria to the clinician? Q10: When do you perform an anti-microbial susceptibility test for strictly anaerobic bacteria? Q11: On which agar do you perform susceptibility testing for strictly anaerobic bacteria? Q12: Which method is used for testing susceptibility of strictly anaerobic bacteria? Q13: Which breakpoints do you use for the interpretation of anaerobic susceptibility testing? Q14: Which anti-microbial agents do you test for anaerobic bacteria? Q15: Do you use non-selective reporting for tested anti-microbial agents? Results and literature review will be discussed

Number a. Survey on anaerobic identification, reporting and AST procedures Q1: From which samples do you perform anaerobic cultures? Results 28 26 24 22 20 18 16 14 12 10 8 6 4 2 0 Always, even if not requested by the clinician If not requested, depending on the clinical context after contacting the clinician Only if requested by the clinician Only if requested by the clinician with additional information Never/Rejection -> Generally accepted sample types for anaerobic culture (rejection 10%)

Number a. Survey on anaerobic identification, reporting and AST procedures Q1: From which samples do you perform anaerobic cultures? Results 30 28 26 24 22 20 18 16 14 12 10 8 6 4 2 0 Always, even if not requested by the clinician If not requested, depending on the clinical context after contacting the clinician Only if requested by the clinician Only if requested by the clinician with additional information Never/Rejection -> Generally rejected sample types for anaerobic culture (rejection 50%)

Number a. Survey on anaerobic identification, reporting and AST procedures Q1: From which samples do you perform anaerobic cultures? Results 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 Broncho-alveolair lavage Middle ear swab Middle ear aspirate Superficial wound aspirate/biopsy Always, even if not requested by the clinician If not requested, depending on the clinical context after contacting the clinician Only if requested by the clinician Only if requested by the clinician with additional information Never/Rejection -> Different opinions exist for these sample types (10% < rejection > 50%)

a. Survey on anaerobic identification, reporting and AST procedures Q1: From which samples do you perform anaerobic cultures? Literature and guidelines 4 important questions (Garcia): 1. Correct sample type? 2. Relevant body site?

a. Survey on anaerobic identification, reporting and AST procedures Q1: From which samples do you perform anaerobic cultures? Literature and guidelines 4 important questions (Garcia): 3. Correct transport device? 4. Transported timely?

a. Survey on anaerobic identification, reporting and AST procedures Q5: When do you perform full ID (species level) of anaerobic colony types? Results Absolute number (%) A full identification is carried out depending on the anatomical origin of the sample 19 (56) A full identification is carried out depending on the number of anaerobic colony types A full identification is carried out of every colony type of which there is a strong suspicion that it is a strictly anaerobic bacteria (comparing aerobic and 13 (38) 13 (38) A full identification is carried out depending on the total ratio of aerobic and anaerobic colony types 6 (18) Other 3 (9) A full identification is carried out of every anaerobic colony type 1 (3)

a. Survey on anaerobic identification, reporting and AST procedures Q5: When do you perform full ID (species level) of anaerobic colony types? Literature and guidelines Pure anaerobic cultures or samples from anatomically sterile sites: CONSENSUS to identify all anaerobic colony types (Garcia; Wadsworth; CLSI M56A) Serious infections: CONSENSUS to identify all anaerobic colony types (Cumitech; Citron et al.; CLSI M56A) Poly-microbial cultures or cultures from non-sterile body sites samples: NO CONSENSUS -> Suggested workup schemes based on Gram stain, biochemical systems and/or rapid disk and spot tests (Baron et al.; Garcia) Using MALDI-TOF: less justifiable to limit anaerobic identifications? -> Figure out workup schemes centralizing MALDI-TOF method -> Introducing restrictive reportage

a. Survey on anaerobic identification, reporting and AST procedures Q9: When do you report full ID of strictly anaerobic bacteria to the clinician? Results Absolute number (%) The full identification is reported depending on the anatomical origine of the sample 18 (53) The full identification is reported depending on the kind of isolated strictly anaerobic bacteria 14 (41) The full identification is reported depending on the number of isolated strictly anaerobic bacteria 14 (41) The full identification is always reported to the clinician 10 (29) The full identification is reported depending on the total ratio of isolated anaerobic and strictly anaerobic bacteria 6 (18) Other 3 (9)

a. Survey on anaerobic identification, reporting and AST procedures Q9: When do you report full ID of strictly anaerobic bacteria to the clinician? Results Which fully identified anaerobic bacteria would you certainly report? (n=14) Absolute number (%) Clostridium species (histolyticum, novyii, perfringens, septicum, sordelii, tertium, botulinum, tetani) Bacteroides fragilis group Fusobacterium species (necrophorum, nucleatum, mortiferum, avium) Actinomyces species Prevotella species (disiens, bivia, dentalis, melaninogenica) Bacteroides non-fragilis group 12 (86) 12 (86) 11 (79) 11 (79) 10 (71) 10 (71) Propionobacterium species 9 (64) Gram positive cocci 2 (14)

a. Survey on anaerobic identification, reporting and AST procedures Q9: When do you report full ID of strictly anaerobic bacteria to the clinician? Literature and guidelines No validated standards for reporting anaerobic bacteria Existing reporting strategies based on knowledge of local and international experts No answer on how and what to report from anaerobic cultures in literature and guidelines Isolation, identification and reportage of anaerobic bacteria justified: 1. Information about potential primary site of infection ( sample origin?) 2. Information about potential resistance ( when performing AST?) 3. Information about virulence ( species matters)

a. Survey on anaerobic identification, reporting and AST procedures Q10: When do you perform AST for strictly anaerobic bacteria? Results Absolute number (%) Depending on the kind of isolated strictly anaerobic bacteria Depending on the anatomical origine of the sample Depending on the number of isolated strictly anaerobic bacteria 13 (38) 13 (38) 10 (29) Always 6 (18) Never Depending on the total ratio of isolated anaerobic and strictly anaerobic bacteria 4 (12) 4 (12) In consultation 2 (6) Depending on clinical data 1 (3)

a. Survey on anaerobic identification, reporting and AST procedures Q10: When do you perform AST for strictly anaerobic bacteria? Results From which anaerobic bacteria would you certainly perform AST? (n=13) Absolute number (%) Bacteroides fragilis group Fusobacterium species (necrophorum, nucleatum, mortiferum, avium) Bacteroides non-fragilis group 11 (85) 9 (69) 9 (69) Prevotella species (disiens, bivia, dentalis, melaninogenica) 7 (54) Clostridium species (histolyticum, novyii, perfringens, septicum, sordelii, tertium, botulinum, tetani) 6 (46) Actinomyces species 5 (38) Propionobacterium species 4 (31) In consultation 2 (15)

a. Survey on anaerobic identification, reporting and AST procedures Q10: When do you perform AST for strictly anaerobic bacteria? Literature and guidelines Major indications for anaerobic AST (CLSI M11-A8): 1. Known resistance of a particular organism or species 2. Persistence of the infection despite adequate treatment with an appropriate therapeutic regimen: manageable? 3. Difficulty in making empirical decisions based on precedent cultures 4. Confirmation of appropriate therapy for severe infections or for those that may require long-term therapy

a. Survey on anaerobic identification, reporting and AST procedures Q10: When do you perform AST for strictly anaerobic bacteria? Literature and guidelines Periodic monitoring of resistance (CLSI M11-A8; Wybo et al.): Resistance especially in Bacteroides and Parabacteroides spp. Amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem and metronidazole suitable for empirical use Penicillin, clindamycin and moxifloxacin not suitable for empiric use Unclear correlation between in vitro susceptibility and clinical response (Brook et al.; Hecht et al): Cure without antibiotics or surgery Cure with surgery Cure with eradication of the aerobic component in poly-microbial infections

Content of this presentation Introduction Questions and methods a. Survey on anaerobic identification, reporting and AST procedures b. Multi-center retrospective case study of anaerobic cultures General conclusions To do/actions

b. Multi-center retrospective case study of anaerobic cultures Demonstrated clinical impact of anaerobic culture results in Bacteroides fragilis bacteremia (Redondo et al; Nguyen et al.; Salonen et al.; Robert et al.) Clinical impact of anaerobic culture results other than blood unclear -> no studies evaluating body fluids, biopsies, abscess drainages, Multi-center retrospective case study conducted: 1. How long does it take to report ID and AST results of anaerobic cultures to clinicians? 2. Is therapy influenced by anaerobic culture reporting practices? 3. Is patient outcome influenced by anaerobic culture reporting practices?

b. Multi-center retrospective case study of anaerobic cultures 7 hospital laboratories documented anaerobic cultures between February 16 and April 5 Inclusion criteria for samples: 1. Aspirate, drainage, biopsy, sterile fluid, surgically obtained deep swabs 2. Anaerobic growth on lab report 3. First isolation of anaerobic bacteria Anonymized reports and coded survey forms 51 relevant samples from 49 different patients

Number b. Multi-center retrospective case study of anaerobic cultures General results Sample types and origin (n=51): 14 12 10 17 deep swabs (33%) 27 aspirates (53%) 8 6 4 2 0 7 tissues (14%)

Number b. Multi-center retrospective case study of anaerobic cultures General results Number of reported species per sample (n=51): 14 12 10 8 6 4 2 0 one two anaerobic anaerobic bacteria bacteria three anaerobic bacteria four aerobic bacteria three aerobic bacteria two aerobic bacteria one aerobic bacteria no aerobic bacteria

Number b. Multi-center retrospective case study of anaerobic cultures General results Isolated anaerobic bacteria (n=63): 14 12 10 8 6 4 2 0

Number b. Multi-center retrospective case study of anaerobic cultures General results Isolated aerobic bacteria (n=93): 25 20 15 10 5 0

Number Number b. Multi-center retrospective case study of anaerobic cultures 1. How long does it take to report ID and AST results of anaerobic cultures to clinicians? 35 30 25 20 15 10 5 0 Reporting time anaerobic bacteria Reporting time ID Reporting time AST Late anaerobic reportage : ID > day 5 AST > day 7 60 50 40 30 20 10 0 Reporting time aerobic bacteria Reporting time ID Reporting time AST Late aerobic reportage : ID > day 3 AST > day 4

b. Multi-center retrospective case study of anaerobic cultures 2. Is therapy influenced by anaerobic culture reporting practices? Anti-microbial therapy in 49 patients: - 7 unknown - 4 none - 38 anti-microbial therapy Documented anti-microbial therapy in 38 patients: - In 7 patients (18%) therapy adjusted based on anaerobic culture results - In 10 patients (26%) therapy adjusted based on aerobic culture results - In 29 patients (76%) empirical therapy whiteout changes afterwards Anaerobic culturing results reported early, completely and with AST results Anaerobic culturing results not reported early, completely or with AST results Anti-microbial therapy not adjusted based on anaerobic ID or AST 15 20 Anti-microbial therapy adjusted based on anaerobic ID or AST 6 1 28% 5% χ 2 -test: p = 0,04

b. Multi-center retrospective case study of anaerobic cultures 3. Is the outcome of patients with anaerobic infections affected by results of anaerobic cultures? 42 (86%) Patient outcome 1 (2%) 3 (6%) 3 (6%) Discharged Still hospitalized with anti-anaerobic therapy Still hospitalized without anti-anaerobic therapy Died Anaerobic culturing results reported early, completely and with AST results Anaerobic culturing results not reported early, completely and with AST results Patient died 2 1 Patient survived 21 25 9% 4% χ 2 -test: p = 0,41

Content of this presentation Introduction Questions and methods a. Survey on anaerobic identification, reporting and AST procedures b. Multi-center retrospective case study of anaerobic cultures General conclusions To do/actions

General conclusions a) Survey on anaerobic identification, reporting and AST procedures: No uniform Belgian laboratory approach concerning anaerobic microbiology practices Suggested evidence-based clinically orientated work-up centralizing MALDI-TOF

General conclusions b) Multi-center retrospective case study of anaerobic cultures: Little use of anaerobic culture results observed Anti-microbial therapy adjusted significantly more, based on anaerobic culture results if reportage was early, completely and with AST Impact on patient outcome, duration of hospitalization or antimicrobial therapy not demonstrated Cave: impact of negative culture result not assessed in this study

Content of this presentation Introduction Questions and methods a. Survey on anaerobic identification, reporting and AST procedures b. Multi-center retrospective case study of anaerobic cultures General conclusions To do/actions

To do/actions Implementation of the clinically orientated workup of anaerobic cultures using MALDI-TOF Continuation of the multi-center retrospective case study in order to demonstrate clinical impact of anaerobic cultures? Literature follow-up ESCMID Study Group for Anaerobic Infections (ESGAI) interested in these results